Raabe N K, Fosså S D, Bjerkehagen B
Department of Clinical Oncology and Radiotherapy, Ullevål Sykehus, Oslo, Norway.
Scand J Urol Nephrol. 1992;26(4):357-61. doi: 10.3109/00365599209181226.
The clinical course and association with other urothelial carcinomas was studied in 80 patients with carcinoma of the renal pelvis. At the time of diagnosis macroscopic haematuria was the most common symptom. Urography and retrograde pyelography gave the most accurate diagnoses. Sixty-eight patients (85%) had transitional cell carcinomas, 39 had a history of another urothelial carcinoma either before or after the diagnosis of the renal tumour, usually in the urinary bladder. A previous urothelial carcinoma together with a small renal tumour were predictive of the subsequent development of another urothelial tumour. Regular cystoscopy is recommended during follow-up because of the short observed interval between the development of carcinoma of the renal pelvis and a subsequent urothelial malignancy. The overall five-year survival was 20%. Survival did not depend on the operation, but was significantly related to the extent of locoregional or distant metastases at the time of diagnosis. Patients with such renal tumours that were preceded by or associated with other urothelial carcinomas had a more favourable median survival (42 months) than patients whose renal tumour was their first urothelial carcinoma (19 months).
对80例肾盂癌患者的临床病程及其与其他尿路上皮癌的关联进行了研究。诊断时,肉眼血尿是最常见的症状。尿路造影和逆行肾盂造影给出了最准确的诊断结果。68例患者(85%)患有移行细胞癌,其中39例在肾肿瘤诊断之前或之后有过其他尿路上皮癌病史,通常发生在膀胱。既往有尿路上皮癌且肾肿瘤较小提示随后可能发生另一种尿路上皮肿瘤。由于肾盂癌发生与随后尿路上皮恶性肿瘤出现之间的观察间隔较短,因此建议在随访期间定期进行膀胱镜检查。总体五年生存率为20%。生存率并不取决于手术方式,而是与诊断时局部区域或远处转移的范围显著相关。有其他尿路上皮癌病史在先或与之相关的肾肿瘤患者,其生存期中位数(42个月)比肾肿瘤是其首个尿路上皮癌的患者(19个月)更为有利。